Respiporc FLUpan H1N1


Porcine influenza vaccine (inactivated)

This medicine is authorised for use in the European Union.


Respiporc FLUpan H1N1 is a vaccine used to protect pigs from eight weeks of age against swine influenza caused by pandemic subtype H1N1. Swine influenza or swine flu is a disease of the lungs and airways in pigs. Signs can include fever, depression, coughing, sneezing, difficulty breathing and loss of appetite. The vaccine can also be used during pregnancy up to three weeks before expected farrowing and during lactation.

The vaccine contains inactivated (killed) influenza A virus/Jena/VI5258/2009(H1N1)pdm09, a strain of the virus that causes swine influenza.

This EPAR was last updated on 21/03/2022

Authorisation details

Product details
Respiporc FLUpan H1N1
Agency product number
Active substance
Influenza A virus/human strain: A/Jena/VI5258/2009 (H1N1)pdm09, inactivated
International non-proprietary name (INN) or common name
Porcine influenza vaccine (inactivated)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
CEVA Santé Animale
Date of issue of marketing authorisation valid throughout the European Union
Contact address

10 avenue de La Ballastière
33500 Libourne

Product information

04/11/2021 Respiporc FLUpan H1N1 - EMEA/V/C/003993 - II/0013

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals, inactivated viral vaccines for pigs, porcine influenza virus

Therapeutic indication

Active immunisation of pigs from the age of 8 weeks onwards against pandemic H1N1 porcine influenza virus to reduce viral lung load and viral excretion.

The vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Assessment history

How useful was this page?

Add your rating